![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1494760
¼¼°èÀÇ Ç¥ÇÇ ¼ºÀåÀÎÀÚ ¼ö¿ëü(EGFR) ¾ïÁ¦Á¦ ½ÃÀå ¿¹Ãø(-2030³â)Epidermal Growth Factor Receptor Inhibitors Market Forecasts to 2030 - Global Analysis By Type, Drug Type, Mode of Administration, Distribution Channel, Application, End User and By Geography |
Stratistics MRC¿¡ µû¸£¸é ¼¼°èÀÇ Ç¥ÇÇ ¼ºÀåÀÎÀÚ ¼ö¿ëü(EGFR) ¾ïÁ¦Á¦ ½ÃÀåÀº 2024³â 141¾ï ´Þ·¯·Î ÃßÁ¤µÇ°í, ¿¹Ãø±â°£ Áß CAGRÀº 14.2%·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 2030³â¿¡´Â 314¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
Ç¥ÇÇ ¼ºÀåÀÎÀÚ ¼ö¿ëü(EGFR) ¾ïÁ¦Á¦´Â ¼¼Æ÷ Ç¥¸é¿¡ Á¸ÀçÇÏ´Â ´Ü¹éÁúÀΠǥÇÇ ¼ºÀåÀÎÀÚ ¼ö¿ëü¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â Á¦Á¦ÀÇ ÀÏÁ¾ÀÔ´Ï´Ù. EGFRÀº ¼¼Æ÷ÀÇ Áõ½Ä°ú ºÐ¿¿¡ °ü¿©Çϰí ÀÖÀ¸¸ç, ±× °úÀ× È°¼ºÀº ¾î¶² À¯ÇüÀÇ ¾Ï, ƯÈ÷ Æó¾Ï°ú ´ëÀå¾ÏÀÇ ¹ß»ý°ú ÁøÇà¿¡ °ü·ÃµÇ¾î ÀÖ½À´Ï´Ù. GFR ¾ïÁ¦Á¦´Â ´Üµ¶ ȤÀº ÈÇпä¹ýÀ̳ª ¹æ»ç¼±¿ä¹ý µîÀÇ ´Ù¸¥ ¾ÏÄ¡·á¿ÍÀÇ º´¿ëÀ¸·Î ´Ù¾çÇÑ ¾ÏÀÇ Ä¡·á¿¡ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.
NIH¿¡ ÀÇÇϸé, ¹Ì±¹¿¡¼´Â ÃÖ±Ù, Æó¾Ï, ´ëÀå¾Ï, À¯¹æ¾Ï µî ´Ù¾çÇÑ À¯ÇüÀÇ ÁÖ¿ä¾ÏÀÇ ½Å±Ô Áõ·Ê°¡ ÇöÀúÇÏ°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. 2020³â¿¡´Â ¹Ì±¹¿¡¼ »õ·Ó°Ô 180¸¸¸íÀÌ ¾ÏÀ¸·Î Áø´ÜµÇ¾î 60¸¸ 6520¸íÀÌ ÀÌ Áúº´À¸·Î »ç¸ÁÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ°í ÀÖ½À´Ï´Ù.
Ç¥Àû Ä¡·á äÅà Ȯ´ë
½ÃÀåÀº ÁøÈÇÏ´Â Ä¡·á »óȲÀ» ¹Ý¿µÇÏ¿© Ç¥Àû ¿ä¹ýÀÇ Ã¤¿ëÀÌ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. Ç¥Àû¿ä¹ýÀº ¾Ï¼¼Æ÷¸¦ ƯÀÌÀûÀ¸·Î Ç¥ÀûÀ¸·Î ÇÔÀ¸·Î½á ¾Ï°ú ½Î¿ì´Â Á¤¹Ðµµ¸¦ ³ô¿© °Ç°ÇÑ Á¶Á÷¿¡ ´ëÇÑ ¼Õ»óÀ» ÃÖ¼ÒÈÇÕ´Ï´Ù. ÀÌ ÆÐ·¯´ÙÀÓ ½ÃÇÁÆ®´Â ¿¬±¸°³¹ßÀÇ Áøº¸¿¡ ´õÇØ ¾ÏÀÇ ÁøÇàÀ» ÃËÁøÇÏ´Â ºÐÀÚ°æ·ÎÀÇ ÀÌÇØ°¡ ÁøÇàµÇ°í ÀÖ´Â °ÍÀÌ ¹è°æ¿¡ ÀÖ½À´Ï´Ù. °³ÀÎÈ Ä¡·á Á¢±Ù¹ýÀÌ º¸±ÞµÊ¿¡ µû¶ó °³º° ȯÀÚ¿¡ ¸Â´Â Ä¡·á·ÎÀÇ ÀüȯÀÌ ÁøÇàµÊ¿¡ µû¶ó ½ÃÀåÀº Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.
´ëü ¿ä¹ýÀÇ °¡¿ë¼º
½ÃÀåÀº ´ëü ¿ä¹ý¿¡ ´ëÇÑ ´ëÀÀÀ̶ó´Â ¹®Á¦¿¡ Á÷¸éÇϰí ÀÖ½À´Ï´Ù. EGFR ¾ïÁ¦Á¦ÀÇ È¿´É¿¡µµ ºÒ±¸Çϰí, ¸é¿ª¿ä¹ý ¹× Ç¥Àû Ä¡·á¿Í °°Àº ´ëü Ä¡·á°¡ °æÀïÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ EGFR ¾ïÁ¦Á¦¿¡ ´ëÇÑ ³»¼º°ú ºÎÀÛ¿ëÀÌ º¹À⼺ÀÇ ¿øÀÎÀÌ µÇ¾ú½À´Ï´Ù. ´ëü ¿ä¹ýÀÇ »ç¿ë ÆíÀǼº, ±¸¸Å ¿ëÀ̼º, ȯÀÚ ÀÎÁöµµ È®º¸´Â ¿©ÀüÈ÷ Áß¿äÇÑ Àå¾Ö¹°ÀÔ´Ï´Ù. ½ÃÀåÀº ÀÌ·¯ÇÑ Ä¡·á¹ýÀ» Ä¡·á ÇÁ·ÎÅäÄÝ¿¡ ÅëÇÕÇϰí ÃÖÀûÀÇ °á°ú¸¦ ¾ò±â À§ÇØ È¯ÀÚ °íÀ¯ÀÇ ¿ä±¸¿¡ ´ëÀÀÇÔÀ¸·Î½á ÀûÀÀÇØ¾ß ÇÕ´Ï´Ù.
¾Ï ÀÌȯÀ² »ó½Â
½ÃÀå¿¡¼´Â ¾Ï ÀÌȯÀ²ÀÇ »ó½ÂÀ̶ó´Â ¿ì·ÁÇØ¾ß ÇÒ °æÇâÀ» º¼ ¼ö ÀÖ½À´Ï´Ù. ¿¤·ÎƼ´ÕÀ̳ª °ÔÇÇÆ¼´Õ µîÀÇ EGFR ¾ïÁ¦Á¦¸¦ ÀÌ¿ëÇÑ Ä¡·á°¡ Áøº¸Çϰí ÀÖÀ½¿¡µµ ºÒ±¸Çϰí, ÀÌ·¯ÇÑ ¿ä¹ý¿¡ ÀÇÁ¸ÇÏ´Â ¾Ï Áõ·ÊÀÇ ¹ß»ý·üÀº Áõ°¡Çϰí ÀÖ½À´Ï´Ù. À̰ÍÀº EGFR¿¡ ±âÀÎÇÏ´Â ¾ÏÀÇ À¯º´·ü Áõ°¡ ¶Ç´Â ÀÌÀü¿¡´Â ÀÌ·¯ÇÑ ¾àÁ¦¿¡ ¹ÝÀÀÇÑ È¯ÀÚ¿¡¼ÀÇ ÀáÀçÀûÀÎ ³»¼º ¹ßÇö Áß ¾î´À °ÍÀ» ³ªÅ¸³¾ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀº ¾Ï »ý¹°ÇÐÀÇ Áö¼ÓÀûÀÎ ¿¬±¸¿Í Çõ½ÅÀûÀÎ Ä¡·á Àü·« °³¹ßÀÇ Çʿ伺À» °Á¶Çϰí ÀÖ½À´Ï´Ù.
°í¾×ÀÇ Ä¡·áºñ
ÀÌ ½ÃÀåÀº °í¾×ÀÇ Ä¡·áºñ¿¡ ÀÇÇÑ °úÁ¦¿¡ Á÷¸éÇϰí ÀÖ¾î ȯÀÚ¿¡°Ô ÀÌ¿ëÇϱ⠾î·Á¿î À庮ÀÌ µÇ°í ÀÖ½À´Ï´Ù. ƯÁ¤ ¾Ï Ä¡·á¿¡ È¿°úÀûÀÓ¿¡µµ ºÒ±¸ÇÏ°í ¾ïÁ¦Á¦ÀÇ °æÁ¦Àû ºÎ´ãÀº ±× È®»êÀ» Á¦ÇÑÇÕ´Ï´Ù. ÀÌ ºñ¿ë ¿äÀÎÀº ±¸¸í Ä¡·á¿¡ ´ëÇÑ °øÁ¤ÇÑ Á¢±ÙÀ» º¸ÀåÇϱâ À§ÇØ ÀÌÇØ °ü°èÀÚ°¡ Çù·ÂÇÏ¿© ´õ Àú·ÅÇÑ ¿É¼ÇÀ» °³¹ßÇϰųª º¸Á¶±ÝÀ» Áö¿øÇÏ´Â ¹æ¹ýÀ» ¸ð»öÇÒ Çʿ伺À» °Á¶ÇÕ´Ï´Ù.
COVID-19ÀÇ À¯ÇàÀº ½ÃÀå¿¡ Å« ¿µÇâÀ» ÁÖ¾ú°í Á¦Á¶, °ø±Þ¸Á ¹× ÀÓ»ó½ÃÇè¿¡ È¥¶õÀ» °¡Á®¿Ô½À´Ï´Ù. Æó¼â ¹× Á¦ÇÑÀ¸·Î ÀÎÇØ ÇコÄÉ¾î ½Ã¼³¿¡ ´ëÇÑ È¯ÀÚÀÇ Á¢±ÙÀÌ ¹æÇصǾî Áø´Ü ¹× Ä¡·áÀÇ ½ÃÀÛ¿¡ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ±×·¯³ª ¿ø°Ý ÀÇ·á ¹× ¿ø°Ý ¸ð´ÏÅ͸µÀÇ µµÀÔÀ¸·Î ¾î´À Á¤µµ Áö¼Ó¼ºÀÌ À¯ÁöµÇ¾ú½À´Ï´Ù. ½ÃÀåÀº ¼ö¿ä º¯µ¿À» ¸ñ°ÝÇϰí ÇʼöÀûÀÎ Ä¡·á¸¦ ¼±È£ÇÏ´Â ¹æÇâÀ¸·Î À̵¿Çß½À´Ï´Ù. °úÁ¦¿¡µµ ºÒ±¸ÇÏ°í ÆÒµ¥¹ÍÀÇ ¾î·Á¿ò °¡¿îµ¥ »õ·Î¿î ¿ä±¸¿¡ ´ëÀÀÇϰí Ä¡·á ¼º°ú¸¦ ÃÖÀûÈÇÏ´Â °ÍÀ» ¸ñÇ¥·Î, Áö¼ÓÀûÀÎ ¿¬±¸ °³¹ßÀÌ ÀÌ·ç¾îÁ³½À´Ï´Ù.
¿¹Ãø±â°£ µ¿¾È º´¿ë¿ä¹ý ºÐ¾ß°¡ ÃÖ´ë°¡ µÉ Àü¸Á
¿¹Ãø ±â°£ µ¿¾È º´¿ë ¿ä¹ý ºÐ¾ß°¡ ÃÖ´ë°¡ µÉ Àü¸ÁÀÔ´Ï´Ù. ¿©·¯ °æ·Î¸¦ µ¿½Ã¿¡ Ç¥ÀûÈÇÔÀ¸·Î½á ÀÌ·¯ÇÑ ¿ä¹ýÀº È¿´ÉÀ» ³ôÀÌ°í ³»¼º ¸ÞÄ¿´ÏÁòÀ» ±Øº¹ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. EGFR ¾ïÁ¦Á¦¿Í ÈÇпä¹ý, ¸é¿ª¿ä¹ý, ±âŸ Ç¥Àû¾àÁ¦¿ÍÀÇ º´¿ë¿ä¹ýÀÌ °ËÅäµÇ°í ÀÖÀ¸¸ç, ´Ù¾çÇÑ ¾ÏÁ¾¿¡¼ °¡´É¼ºÀÌ ³ªÅ¸³µ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù¹ýÀº °³ÀÎÈµÈ Ä¡·á ¿ä¹ý¿¡ ´ëÇÑ »õ·Î¿î ±æÀ» Á¦°øÇϰí, ÀÌÁ¾ Á¾¾ç ÇÁ·ÎÆÄÀÏ ¹× ÀûÀÀ¼º ÀúÇ× ¸ÞÄ¿´ÏÁò¿¡ ´ëóÇÔÀ¸·Î½á ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±½Ãų ¼ö ÀÖ½À´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È CAGRÀÌ °¡Àå ³ôÀº °ÍÀº ´ëÀå¾Ï ºÎ¹®ÀÔ´Ï´Ù.
´ëÀå¾Ï ºÐ¾ß´Â Ç¥Àû Ä¡·áÀÇ Áøº¸·Î ¿¹Ãø ±â°£ Áß¿¡ °¡Àå ³ôÀº CAGRÀÌ ¿¹»óµË´Ï´Ù. ¼¼Åö½Ã¸¿ ¹× ÆÄ´ÏÅõ¹«¸¿°ú °°Àº ÀÌ·¯ÇÑ ¾ïÁ¦Á¦´Â EGFR ½ÅÈ£Àü´Þ °æ·Î¸¦ ¾ïÁ¦ÇÔÀ¸·Î½á ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±½ÃŰ´Â À¯¸ÁÇÑ °á°ú¸¦ ³ªÅ¸³À´Ï´Ù. ¼¼°èÀÇ ´ëÀå¾Ï À¯º´·ü »ó½Â°ú ¸ÂÃãÇü Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁü¿¡ µû¶ó EGFR ¾ïÁ¦Á¦ ½ÃÀåÀº Å©°Ô ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.
ºÏ¹Ì´Â ¾Ï ÀÌȯÀ² Áõ°¡³ª Ç¥Àû Ä¡·áÀÇ Áøº¸ µîÀÇ ¿äÀο¡ ÀÇÇØ ¿¹Ãø ±â°£ Áß ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Á¤¹ÐÀÇ·á¿¡ ÃÊÁ¡À» ¸ÂÃá ÀÌ·¯ÇÑ ¾ïÁ¦Á¦´Â Æó¾Ï°ú ´ëÀå¾Ï µî ´Ù¾çÇÑ ¾Ï Ä¡·á¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀÇ ÁÖ¿ä ±â¾÷µéÀº Çõ½ÅÀûÀÎ Ä¡·á¹ýÀÇ µµÀÔÀ» ¸ñÇ¥·Î ¿¬±¸°³¹ß¿¡ °è¼Ó ÅõÀÚÇϰí ÀÖ½À´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ °¡Àå ³ôÀº CAGRÀ» À¯ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ Áö¿ª¿¡¼´Â Æó¾ÏÀ̳ª ´ëÀå¾Ï µî EGFR ¾ïÁ¦Á¦·Î Ä¡·áµÇ´Â °æ¿ì°¡ ¸¹Àº ¾ÏÀÇ ÀÌȯÀ²ÀÌ »ó½ÂÇϰí ÀÖ½À´Ï´Ù. ¾Ï¿¡ ´ëÇÑ ÀǽÄÀÇ ³ô¾ÆÁü°ú °ËÁø ÇÁ·Î±×·¥ÀÇ Ãæ½ÇÀÌ ¾ÏÀÇ Á¶±â ¹ß°ßÀ¸·Î ¿¬°áµÇ¾î, ±× °á°ú, Ç¥Àû Ä¡·áÀÇ ´ë»óÀÌ µÇ´Â ȯÀÚ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ÀÇ·áºñ¿Í ÀǽÄÀÌ ³ô¾ÆÁö¸é¼ ½ÃÀåÀÇ ¼ºÀåÀ» ´õ¿í µÞ¹ÞÄ§ÇØ ÁøÇàÁßÀÎ ÀÓ»ó½ÃÇè°ú Á¦Ç°»ó½Ã¸¦ Ư¡À¸·Î ÇÏ´Â °æÀï ±¸µµ¸¦ Á¶¼ºÇϰí ÀÖ½À´Ï´Ù.
According to Stratistics MRC, the Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market is accounted for $14.1 billion in 2024 and is expected to reach $31.4 billion by 2030 growing at a CAGR of 14.2% during the forecast period. Epidermal Growth Factor Receptor (EGFR) inhibitors are a class of medications that target the epidermal growth factor receptor, a protein found on the surface of cells. EGFR is involved in cell growth and division, and its overactivity is associated with the development and progression of certain types of cancer, particularly lung cancer and colorectal cancer. GFR inhibitors are used in the treatment of various cancers, either alone or in combination with other cancer therapies, such as chemotherapy or radiation therapy.
According to the NIH, the new cases of various types of major cancers, such as lung cancer, colorectal cancer, and breast cancer, in the US have increased significantly in recent years. In 2020, an estimated 1.8 million new cases of cancer were diagnosed in the US, and 606,520 people will die from the disease.
Growing adoption of targeted therapies
The market is witnessing a surge in adoption of targeted therapies, reflecting an evolving treatment landscape. Targeted therapies offer precision in combating cancer by specifically targeting cancer cells, minimizing damage to healthy tissue. This paradigm shift is driven by advancements in research and development, alongside increasing understanding of molecular pathways driving cancer progression. With personalized treatment approaches gaining traction, the market is poised for substantial growth as it moves towards tailored therapies for individual patients.
Availability of alternative therapies
The market faces challenges in accommodating alternative therapies. Despite the effectiveness of EGFR inhibitors, alternative treatments like immunotherapy and targeted therapies pose competition. Additionally, resistance to EGFR inhibitors and adverse effects contribute to the complexity. Ensuring accessibility, affordability, and patient awareness of alternative therapies remain key hurdles. The market must adapt by integrating these therapies into treatment protocols and addressing patient-specific needs for optimal outcomes.
Rising cancer rates
The market has seen a concerning trend of rising cancer rates. Despite advancements in treatment utilizing EGFR inhibitors, such as Erlotinib and Gefitinib, the incidence of cancer cases reliant on these therapies has increased. This may indicate either a growing prevalence of EGFR-driven cancers or potential resistance development in patients previously responsive to these drugs. Such trends underscore the need for continued research into cancer biology and the development of innovative therapeutic strategies.
High cost of treatment
The market faces challenges due to high treatment costs, posing a barrier to accessibility for patients. Despite their efficacy in treating certain cancers, the financial burden associated with these inhibitors limits their widespread adoption. This cost factor underscores the need for collaborative efforts among stakeholders to develop more affordable options or explore avenues for subsidization to ensure equitable access to life-saving treatments.
The COVID-19 pandemic significantly impacted the Market, causing disruptions in manufacturing, supply chains, and clinical trials. Lockdowns and restrictions hindered patient access to healthcare facilities, affecting diagnosis and treatment initiation. However, with the adoption of telemedicine and remote monitoring, some continuity was maintained. The market witnessed fluctuations in demand, with a shift towards prioritizing essential treatments. Despite challenges, ongoing research and development efforts persisted, aiming to address emerging needs and optimize therapeutic outcomes amidst the pandemic's challenges.
The combination therapies segment is expected to be the largest during the forecast period
The combination therapies segment is expected to be the largest during the forecast period. By targeting multiple pathways simultaneously, these therapies aim to enhance efficacy and overcome resistance mechanisms. Combinations of EGFR inhibitors with chemotherapy, immunotherapy, and other targeted agents are being explored, showing potential in various cancer types. Such approaches offer new avenues for personalized treatment regimens and may improve patient outcomes by addressing heterogeneous tumor profiles and adaptive resistance mechanisms.
The colorectal cancer segment is expected to have the highest CAGR during the forecast period
The colorectal cancer segment is expected to have the highest CAGR during the forecast period driven by advancements in targeted therapies. These inhibitors, such as cetuximab and panitumumab, have shown promising results in improving patient outcomes by inhibiting EGFR signaling pathways. With increasing prevalence of colorectal cancer globally, coupled with growing demand for personalized treatment approaches, the EGFR inhibitors market is poised for significant growth.
North America is projected to hold the largest market share during the forecast period driven by factors such as increasing cancer prevalence and advancements in targeted therapies. With a focus on precision medicine, these inhibitors play a crucial role in treating various cancers, including lung and colorectal cancer. Key players in the region continue to invest in research and development, aiming to introduce innovative therapies.
Asia Pacific is projected to hold the highest CAGR over the forecast period. The region has witnessed a rise in the incidence of cancer, including lung cancer and colorectal cancer, which are often treated with EGFR inhibitors. Increasing awareness about cancer and the availability of screening programs have led to earlier detection of cancers, resulting in more patients being eligible for targeted therapies. Moreover, rising healthcare expenditure and awareness further bolster market growth, fostering a competitive landscape characterized by ongoing clinical trials and product launches.
Key players in the market
Some of the key players in Epidermal Growth Factor Receptor (EGFR) Inhibitors market include Novartis AG, F. Hoffmann-La Roche Ltd, Merck & Co., Amgen Inc, Eli Lilly and Company, OSI Pharmaceuticals Inc, Johnson & Johnson, Genentech, Inc, Pfizer, AstraZeneca PLC, Bayer AG, AbbVie, Bristol Myers Squibb, Teva Pharmaceutical Industries, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim and Regeneron Pharmaceuticals.
In May 2023, Eli Lilly and Innovent Biologics, Inc. jointly announced that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) for TYVYT(R) (sintilimab injection) in combination with bevacizumab and chemotherapy (pemetrexed and cisplatin) in patients with epidermal growth factor receptor (EGFR)-mutated non-squamous non-small cell lung cancer (NSCLC).
In September 2022, Novartis announced results from a new pooled exploratory analysis across the entire MONALEESA Phase III program, confirming nearly one year of additional overall survival (OS) benefit in a subgroup of patients with aggressive forms of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer (aBC)1.